Publications by authors named "Howard McLeod"

Are you Howard McLeod?   Register this Author




Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.
Contemp Clin Trials 2018 May 10;68:7-13. Epub 2018 Mar 10.
Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA; Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA; Clinical and Translational Science Institute, University of Florida, Gainesville, FL, USA. Electronic address:






Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients.
Oncotarget 2018 Feb 6;9(15):12164-12173. Epub 2018 Jan 6.
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan, China.


Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors.
Oncotarget 2017 Dec 4;8(70):115114-115127. Epub 2017 Dec 4.
DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.
Pharmacotherapy 2017 Sep 2;37(9):1043-1051. Epub 2017 Apr 2.
Division of Population Science, DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort.
J Invest Dermatol 2017 Sep 23;137(9):2021-2023. Epub 2017 May 23.
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. Electronic address:

EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients.
Clin Chim Acta 2017 Aug 7;471:216-221. Epub 2017 Jun 7.
Department of Clinical Pharmacology, Xiangya Hospital, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China; Moffitt Cancer Center, DeBartolo Family Personalized Medicine Institute, Tampa, FL, USA. Electronic address:


A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
Lancet Oncol 2017 Feb 18;18(2):202-211. Epub 2016 Dec 18.
Department of Radiation Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Department of Chemical Biology and Molecular Medicine, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address:




A comparison of DMET Plus microarray and genome-wide technologies by assessing population substructure.
Pharmacogenet Genomics 2016 Jan 1. Epub 2016 Jan 1.
aDepartment of Statistics bBioinformatics Research Center, North Carolina State University cOrtelion LLC dPharmacogenetics for Every Nation Initiative, Raleigh, North Carolina eDeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA fXiangya Hospital, Central South University, Changsha, China.

PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics.
Pharmacogenet Genomics 2015 Dec;25(12):622-30
Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDepartment of Anesthesiology dMoffitt Cancer Center, DeBartolo Family Personalized Medicine Institute, Tampa, Florida, USA eGenomics England, Queen Mary University of London, London, UK.


Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).
J Natl Cancer Inst 2015 Oct 9;107(10). Epub 2015 Jul 9.
Personalized Medicine, Mission Cancer Care, Mission Health, Asheville, NC (LGD); Biostatistics Core, Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill, NC (AMD); Alliance Statistics and Data Center, Duke University, Durham, NC (formerly the Cancer and Leukemia Group B Statistical and Data Management Center, Duke University, Durham, NC) (KO); GlaxoSmithKline, Research Triangle Park, NC (DW); Independent contractor, Williamsville, NY (KD); Department of Medicine and Center for Personalized Therapeutics, University of Chicago, Chicago, IL (PNF, MJR); DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, FL (HLM).

Single-Nucleotide Polymorphisms in Cytochrome P450 2E1 (CYP2E1) 3'-Untranslated Region Affect the Regulation of CYP2E1 by miR-570.
Drug Metab Dispos 2015 Oct 21;43(10):1450-7. Epub 2015 Jul 21.
Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan (Ma.N., T.M., T.F., Mi.N.); Department of Legal Medicine, School of Medicine, Iwate Medical University, Morioka, Japan (M.T., Y.A.); Department of Medicine, School of Medicine, Washington University, St. Louis, Missouri (H.L.M.)

Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups.
Pharmacogenomics 2015 Jul 17;16(8):817-24. Epub 2015 Jun 17.
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, PR China.



A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy.
Oncologist 2014 Sep 12;19(9):959-65. Epub 2014 Aug 12.
Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA; Eshelman School of Pharmacy, Institute for Pharmacogenomics and Individualized Therapy, and Biostatistics Core, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA; Indiana University Simon Cancer Center, Indianapolis, Indiana, USA; Cone Health Cancer Center, Greensboro, North Carolina, USA; Rex Healthcare, Raleigh, North Carolina, USA; Leo W. Jenkins Cancer Center, Greenville, North Carolina, USA; Marion L. Shepard Cancer Center, Washington, North Carolina, USA; Cancer Care of Western North Carolina, Asheville, North Carolina, USA; Moffitt Cancer Center, Tampa, Florida, USA.

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
Breast Cancer Res Treat 2014 May 6;145(1):245-54. Epub 2014 Apr 6.
Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, 428 Church St, Ann Arbor, MI, 48109, USA,

Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology.
Clin Cancer Res 2014 May;20(10):2530-40
Authors' Affiliations: Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan; Moffitt Cancer Center; and DeBartolo Family Personalized Medicine Institute, Tampa, FloridaAuthors' Affiliations: Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan; Moffitt Cancer Center; and DeBartolo Family Personalized Medicine Institute, Tampa, Florida

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
J Clin Oncol 2014 Apr 3;32(10):1031-9. Epub 2014 Mar 3.
Dan Rosmarin, Claire Palles, David Church, Enric Domingo, Angela Jones, Ian Tomlinson, Wellcome Trust Centre for Human Genetics, NIHR Comprehensive Biomedical Research Centre, University of Oxford; Dan Rosmarin, David Church, Elaine Johnstone, Haitao Wang, Sharon Love, Patrick Julier, Claire Scudder, George Nicholson, Rachel Midgley, David Kerr, and George Nicholson, University of Oxford, Oxford; Michael Braun, The Christie NHS Foundation Trust, Manchester; Matthew Seymour, St James's University Hospital, Leeds; Lindsay Thompson, Medical Research Council Clinical Trials Unit; Rohini Sharma, Imperial College Healthcare NHS Trust, Hammersmith and Charing Cross Hospitals, London, United Kingdom; Anna Gonzalez-Neira, Spanish National Cancer Research Centre; Miguel Martin, Instituto de Investigacion Sanitaria Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid; Nuria Ribelles, Hospital Universitario Virgen de la Victoria, Málaga; Eva Martinez-Balibrea, Institut Català d'Oncologia, Institut de Recerca Sanitària Germans Trias i Pujol, Barcelona; Jesus Garcia-Foncillas, University Clinic of Navarra, University of Navarra, Pamplona, Spain; Daniel Sargent, Erin Green, Mayo Clinic, Rochester, MN; Howard McLeod, University of North Carolina, Chapel Hill, NC; Ulrich M. Zanger, Matthias Schwab, Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart; Ulrich M. Zanger, Matthias Schwab, University Hospital Tuebingenl, Tuebingen, Germany; Benjamin Lacas, Valérie Boige, Jean-Pierre Pignon, Institut Gustave Roussy, Villejuif; Marie-Christine Etienne-Grimaldi, Gérard Milano, Centre Antoine Lacassagne, Nice; Thierry Lecomte, Pierre Laurent-Puig, Assistance Publique Hopitaux de Paris, Hopital Européen Georges Pompidou, Paris; Alain Morel, Institut National de la Sante et de la Recherche Medicale U564, Centre Paul Papin, Angers, France; Shoaib Afzal, Henrik Enghusen, Laboratory of Clinical Pharmacology, Rigshospitalet, Copenhagen; Sør


Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.
Clin Cancer Res 2013 Oct 20;19(20):5769-76. Epub 2013 Aug 20.
Authors' Affiliations: Schools of Pharmacy and Medicine; Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill; Bioinformatics Research Center and Department of Statistics, North Carolina State University; The Beatson Oncology Centre, University of Glasgow, Glasgow; and Department of Oncology, Imperial College London, London, United Kingdom.

Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial.
Pharmacogenomics 2013 Oct;14(13):1593-603
Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, 5034 Old Clinic Building, CB #7110, Chapel Hill, NC 27599, USA.


VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians.
Thromb Haemost 2013 Jun 21;109(6):1045-50. Epub 2013 Mar 21.
Center for Pharmacogenomics, University of Florida, Health Science Center, PO Box 100486, Gainesville, FL 32610, USA.

Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
Breast Cancer Res Treat 2013 May 16;139(1):135-43. Epub 2013 Apr 16.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1-1M52, Baltimore, MD 21231, USA.

Nomenclature for alleles of the thiopurine methyltransferase gene.
Pharmacogenet Genomics 2013 Apr;23(4):242-8
Department of Medical and Health Sciences, Division of Drug Research, Faculty of Health Sciences, Linköping University, Linköping, Sweden.

The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
Pharmacogenet Genomics 2013 Jan;23(1):29-33
Sections of Clinical Pharmacology and Hematology/Oncology, Department of Medicine, The Geisel School of Medicine at Dartmouth, The Norris Cotton Cancer Center, Lebanon, NH 03756, USA.

A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
Clin Cancer Res 2012 Sep 27;18(18):5099-109. Epub 2012 Jul 27.
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, 1550 4th Street RH584E, San Francisco, CA 94158-2911, USA.

Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome.
PLoS One 2012 27;7(7):e41954. Epub 2012 Jul 27.
Division of Pharmacotherapy and Experimental Therapeutics, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells.
PeerJ 2013 12;1:e31. Epub 2013 Feb 12.
Lineberger Comprehensive Cancer Center , University of North Carolina at Chapel Hill , NC , USA ; Division of Hematology/Oncology , University of North Carolina at Chapel Hill , NC , USA ; UNC Institute for Pharmacogenomics and Individualized Therapy , University of North Carolina at Chapel Hill , NC , USA.

The prognostic value of altered eIF3a and its association with p27 in non-small cell lung cancers.
PLoS One 2014 30;9(4):e96008. Epub 2014 Apr 30.
Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan 8, P. R. China.

Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
PLoS One 2014 18;9(9):e107424. Epub 2014 Sep 18.
Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, United States of America.



Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway.
Oncotarget 2016 10;7(42):68314-68327
Department of Clinical Pharmacology, XiangYa Hospital, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China.


Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.
Pharmacogenet Genomics 2017 11;27(11):402-409
aDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan bUNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina cDeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida dDepartment of Clinical Pharmacology, Indiana University, Indianapolis, Indiana eBon Secours Cancer Institute, Richmond, Virginia, USA.

miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β-catenin/EMT signaling cascade in gastric cancer.
BMC Cancer 2017 12 22;17(1):886. Epub 2017 Dec 22.
Department of General Surgery, Xiangya Hospital of Central South University, No.87 Xiangya Road, Changsha, 410008, People's Republic of China.

OF